Navigation Links
Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
Date:2/1/2013

LAKE FOREST, Calif., Feb. 1, 2013 /PRNewswire/ -- TRIMEDYNE, INC. (OTCBB "TMED") reported revenues of $6,080,000 for the fiscal year ended September 30, 2012, a 9% decrease from revenues of $6,656,000 for the prior fiscal year.  The decrease in revenues was largely due to a decrease in sales of Lasers, partially offset by an increase in sales of Fibers, Needles and Tips.

The Company had an operating loss of $1,170,000 for the 2012 fiscal year, compared to an operating loss of $1,522,000 for the prior fiscal year.  Due to economies instituted in the past year, the Company had net loss of $836,000 or $0.05 per share for the fiscal year ended September 30, 2012, as compared to a net loss of $1,486,000 or $0.08 per share for the prior fiscal year.

For the quarter ended September 30, 2012, the Company had revenues of $1,449,000, a 16% decrease from revenues of $1,732,000 for the same quarter of the prior year.  Due to economies instituted in the past year, the Company had an operating loss of $340,000 for the quarter ended September 30, 2012, compared to an operating loss of $683,000 for the same quarter of the prior year.  The Company had a net loss of $314,000 or $0.02 per share for the quarter ended September 30, 2012, versus a net loss of $689,000 or $0.04 per share for the year earlier quarter.

Included in the cost of sales for the fiscal year and quarter ended September 30, 2012, was a charge for excess and obsolete inventory of $225,000.  Without this non-cash charge, the Company's loss from operations for the fiscal year and quarter ended September 30, 2012, would have been $945,000 and $115,000, respectively, and the Company's net loss for the fiscal year and quarter ended September 30, 2012, would have been $611,000 and $89,000, respectively.

The Company ended the 2012 fiscal year with cash and equivalents of $472,000 and receivables and other current assets of $651,000, versus accounts payable and accrued expenses of $501,000.

The Company is aggressively pursuing financing for the seven (7) subsidiaries the Company plans to organize to conduct clinical trials of the Company's breakthrough lasers and optical fiber devices to treat a variety of medical conditions, as described in the Company's Press Release of November 28, 2012.

Trimedyne manufactures proprietary Holmium lasers and patented fiber optic laser devices for vaporizing the prostate to treat BPH, vaporizing spinal disc tissue to treat herniated or ruptured discs and in a variety of other, minimally invasive procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery.  For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.    

"Safe Harbor" Statement Under  the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect", "may", "could" and others.  Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC reports.  There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

CONTACT:

Jeffrey Rudner


(949) 951-3800, Ext. 285


jrudner@trimedyne.com


'/>"/>
SOURCE Trimedyne, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
(Date:2/11/2016)... 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced ... 31, 2015. The Company also filed its Quarterly Report on ... with the Securities and Exchange Commission today. ... --> --> Net sales ... million, or 95%, to $5.4 million from $2.8 million for ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV ... , The increasingly modern world of instantaneous consumption proves very convenient for businesses. ... such as oil and coal, which pollutes our air, water, and soil. It can ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... Outlook’s top Clinical Data Management Solution Providers list for its expertise in eClinical ... and domain expertise to serve the technology needs of global clients. DDi provides ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Fisher House ... Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy ... at the VA Southern Nevada Healthcare System. This will be the first Fisher ...
Breaking Medicine News(10 mins):